PARADIGM BIOPHARMACEUTICALS LTD (ASX: PAR) Given go ahead for the Non Opioid IND Phase 3 trials of ZILOSUL for OSTEOARTHRITISASX RELEASE 3rd November 2021
PARADIGM’s INVESTIGATIONAL NEW DRUG (IND) APPLICATION
CLEARED BY THE US FDA.
PHASE 3 STUDY IN KNEE OA CAN COMMENCE IN USA.
https://hotcopper.com.au/threads/ann-paradigm-cleared-for-phase-3-trial-by-us-fda.6397526/?source=email
This is a non opioid repurposed drug used for over 60 years in the veterinary trade on horses, dogs and cats. Set for trials in America, European Union, and Australia
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
is there a us ticker ?
No, not as yet. That’s part of the mystery of this company. Only in Australia, and no mention yet of cross listing in the US.
A great site in Australia is Hot Copper:
https://hotcopper.com.au/asx/par/
Here are their websites:
https://paradigmbiopharma.com/
https://www.linkedin.com/company/paradigm-biopharmaceuticals/
https://twitter.com/ParadigmBio
As always do your own research and due diligence. Investing in Biopharma requires patience.
Best of luck in all of your investments!
PAR:ASX
8 November 2021 09:00am (AEDT)
PAR: Global Market Research indicates price for Zilosul
KEY HIGHLIGHTS
• Global market research conducted to better understand willingness-to-pay and
willingness-to prescribe Zilosul® for osteoarthritis (OA) of the knee (kOA).
• Research indicates projected price of US$2-3K p.a likely for Zilosul® as a therapy
to reduce pain and improve function.
• If future data support a DMOAD label extension by the US Food and Drug
Administration (FDA) then price per year of therapy in the United States could increase
to US$6K p.a. and potentially higher.
• With projections of 50% of patients likely to be offered Zilosul® as a therapy to manage
the pain and functional impairment of kOA, and even higher uptake if used as an earlier
intervention for disease modification, this research confirms the blockbuster potential
for Zilosul®
https://hotcopper.com.au/threads/ann-global-market-research-indicates-price-for-zilosu.6406508/?source=email
$PAR:ASX
ASX RELEASE 9th November 2021
Paradigm Presentation at the Bell Potter Healthcare Conference
https://hotcopper.com.au/threads/ann-paradigm-presentation-to-bell-potter-healthcare-conference.6409646/
$PAR:ASX
Ann: Paradigm welcomes Dr Reiter from bene pharmaChem to the team
https://hotcopper.com.au/threads/ann-paradigm-welcomes-dr-reiter-from-bene-pharmachem-to-the-team.6429113/
$PAR:ASX
Ann: Paradigm CEO Paul Rennie to transition to Non-Exec Chairman
https://hotcopper.com.au/threads/ann-paradigm-ceo-paul-rennie-to-transition-to-non-exec-chairman.6435605/
$PAR:ASX
Ann: Preliminary Results from Phase 2 MPS I Study
https://hotcopper.com.au/threads/ann-preliminary-results-from-phase-2-mps-i-study.6438221/
$PAR:ASX
Ann: FDA Grants Paradigm Fast Track Designation For OA
https://hotcopper.com.au/threads/ann-fda-grants-paradigm-fast-track-designation-for-oa.6691382/?source=email
$PAR:ASX
Paradigm Biopharmaceuticals Ltd Chief Medical Officer and Interim CEO Dr. Donna Skerrett tells Proactive the Melbourne, Australia-based clinical stage biopharmaceutical company has been granted Fast Track Designation for the company’s phase 3 program to treat osteoarthritis.
https://www.youtube.com/watch?v=qrhECxdGWv0
Paradigm Biopharmaceuticals Limited (ASX: PAR) – Trading
Halt
Release Date: 31/03/23 09:21
Summary: Trading Halt
Price Sensitive: Yes
Download Document 624.8KB
https://hotcopper.com.au/threads/ann-trading-halt.7310131/